



1656
RECEIVED

I hereby certified that this correspondence is being deposited with the United States
Postal Services on the date set forth below as First Class Mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231.
Date of Signature 10/17/00 Jean C. Bahr TECH CENTER 1600/2500
and Deposit: #6

Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 11/3/00

Applicants: Kelly J. Henrickson and Jiang Fan
Serial No.: 09/484,704
Filed: January 18, 2000
For: VIRUS ASSAY METHOD
Group Art Unit: 1656
Examiner: J. Siew

Commissioner for Patents
Washington, D.C. 20231

RESPONSE

Dear Sir:

In the matter of the September 19, 2000 Office
Action and in the matter of the above-identified case,
Applicants respectfully request the following remarks be
entered.

Remarks

The Examiner has asked for an election to ten
nucleotide sequences. Applicants choose SEQ ID NOS:1-9
and indicate that claims 1, 2, 3, 4, 5, 7, 8, 9, 10, 11,
13, 14, 15, 16, 17, 18, 19, 21, 22, 24, 25, 26, 27, 28,
29, 30, 32 and 33 do not claim SEQ ID NOS beyond SEQ ID
NOS:1-9 and their inverse complements. Applicants are
uncertain as to whether claims that introduce extra genes
into the method claim, such as claim 3, without

introducing new SEQ ID NOs. would exceed the Examiner's
"ten sequence requirement." If this is the case,
Applicants still elect claims drawn to SEQ ID NOs:1-9 and
inverse complements.

Respectfully submitted,

Kelly J. Henrickson
and Jiang Fan

October 16, 2000

By: 

Jean C. Baker
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 35,433
(414) 277-5709